Clinical trials demonstrated the benefit of PCSK9 inhibition: administration of the anti-PCSK9 antibody evolocumab to patients with a recent myocardial infarction significantly reduced the risk of the composite outcome of cardiovascular death [36]; the combination of a PCSK9 antibody (alirocumab) with statin therapy reduced the occurrence of both type 1 and type 2 myocardial infarction in patients with recent acute coronary syndrome and dyslipidemia [37]. Here, PCSK9 is linked to acute coronary syndrome.